id: NEW:nonalcoholic_fatty_liver_disease_nafld_to_metabolic_syndrome_prevalence
name: Nonalcoholic Fatty Liver Disease (NAFLD) â†’ Metabolic Syndrome Prevalence
from_node:
  node_id: NEW:nonalcoholic_fatty_liver_disease_nafld
  node_name: Nonalcoholic Fatty Liver Disease (NAFLD)
to_node:
  node_id: metabolic_syndrome_prevalence
  node_name: Metabolic Syndrome Prevalence
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: NAFLD develops from hepatic fat accumulation, often driven by insulin resistance
  and metabolic dysfunction'
- 'Step 2: The diseased liver exhibits impaired glucose and lipid metabolism, exacerbating
  systemic insulin resistance'
- 'Step 3: Hepatic inflammation and altered adipokine/hepatokine secretion promote
  dyslipidemia, hypertension, and glucose intolerance'
- 'Step 4: These metabolic derangements collectively manifest as new-onset metabolic
  syndrome components (hypertension, dyslipidemia, diabetes)'
- 'Step 5: The incidence rate of metabolic syndrome in NAFLD patients is 25.4 per
  1,000 person-years, indicating substantial progression to full metabolic syndrome'
evidence:
  quality_rating: A
  n_studies: 79
  primary_citation: 'M. Le et al. 2024. Global incidence of adverse clinical events
    in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinical
    and Molecular Hepatology.'
  supporting_citations: []
description: NAFLD significantly increases the incidence of metabolic syndrome, with
  a pooled incidence rate of 25.4 per 1,000 person-years. This meta-analysis of 79
  studies (1,377,466 persons) demonstrates that NAFLD promotes the development of
  metabolic syndrome components including hypertension (25.8/1,000 PY), dyslipidemia
  (26.4/1,000 PY), and diabetes (19.0/1,000 PY). The bidirectional relationship between
  hepatic steatosis and systemic metabolic dysfunction creates a progressive cycle
  of metabolic deterioration.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 25.4
    type: incidence_rate_per_1000_person_years
    ci_lower: null
    ci_upper: null
  p_value: null
  sample_size: 1377466
moderators:
- name: NASH status
  direction: strengthens
  strength: moderate
  description: Biopsy-proven NASH (present in 58.85% of cohort) associated with higher
    incidence of adverse outcomes including hepatocellular carcinoma
- name: Geographic region
  direction: strengthens
  strength: moderate
  description: North America and Europe showed higher rates of CVD and mortality;
    North America showed higher hypertension and non-liver cancer rates
- name: Time period
  direction: strengthens
  strength: weak
  description: Time-period analyses showed changing rates over time, with decreasing
    cardiovascular and non-liver cancer mortality but increasing decompensated cirrhosis
    rates
